Nine Masts Capital’s Filana Therapeutics FLNA Stock Holding History

Nine Masts Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,107	Closed	-$45.8K	–	279
2026 Q1	$45.8K	Buy	+27,107	New	+$55.8K	0.01%	150

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Nine Masts Capital's FLNA Position: Q2 2026 in Review

Nine Masts Capital sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 27,107 shares — an estimated $45.8K sold.

Nine Masts Capital first reported a position in FLNA in Q1 2026 and held it in 1 quarter. The position peaked at $45.8K in Q1 2026. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Nine Masts Capital reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 27,107 Filana Therapeutics shares in Q2 2026, an estimated $45.8K.
Nine Masts Capital first reported a position in Filana Therapeutics in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Filana Therapeutics position peaked at $45.8K in Q1 2026.
85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.